Correction for Kempker et al., “A Pharmacology Perspective on Simultaneous Tuberculosis and Hepatitis C Treatment”

Russell R. Kempker,^a Wael A. Alghamdi,^b Mohammad H. Al-Shaer,^c Gena Burch,^c Charles A. Peloquin^c

^aDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA

^bDepartment of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia

^cDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida, USA

Volume 63, no. 12, e01215-19, 2019, <https://doi.org/10.1128/AAC.01215-19>. Page 7 of the PDF, 3rd full paragraph, 1st sentence: “The combination of elbasvir and grazoprevir is approved for HCV genotypes 1 to 4” should read “The combination of elbasvir and grazoprevir is approved for HCV genotypes 1 and 4.”

Citation Kempker RR, Alghamdi WA, Al-Shaer MH, Burch G, Peloquin CA. 2020. Correction for Kempker et al., “A pharmacology perspective on simultaneous tuberculosis and hepatitis C treatment.” *Antimicrob Agents Chemother* 64:e02358-19. <https://doi.org/10.1128/AAC.02358-19>.

Copyright © 2020 American Society for Microbiology. All Rights Reserved.

Address correspondence to Russell R. Kempker, rkempke@emory.edu.

Published 27 January 2020